Dimerix Ltd (ASX:DXB, OTC:SBMJF) CEO and managing director Dr Nina Webster is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth.
Dimerix is is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need.
Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with inflammatory diseases, such as kidney or lung diseases. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.